Sidoti & Co Upgrades Meridien Bioscience (VIVO) to Buy
More News related to VIVO
- Meridian Biosci. (VIVO) Posts Q4 EPS of $0.22, Tops by 1c
- Meridian Bioscience Reports Record Fiscal 2009 Operating Results, Increases Regular Cash Dividend Rate, and Reaffirms Guidance
- Trading Radar for 11/12: Wal-Mart (WMT), Blockbuster (BBI), Nordstrom (JWN), Walt Disney (DIS), Kohl's (KSS) Report
- Sidoti & Co Upgrades Meridien Bioscience (VIVO) to Buy
- Meridian Bioscience (VIVO) In Agreement to Distribute Test For GI Disease in Europe
Sidoti & Co upgrades Meridien Bioscience (Nasdaq: VIVO) from Neutral to Buy. Price target $28.
To see more analyst ratings on VIVO Click Here.
Meridian Bioscience, Inc., a life science company, engages in the development, manufacture, sale, and distribution of diagnostic test kits primarily for respiratory, gastrointestinal, viral, and parasitic infectious diseases.
Related Categories
UpgradesStocks Mentioned
-0.22Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
